Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / RPSA



This biomarker is also known as:
  • laminin receptor 1 (67kD, ribosomal protein SA),
  • Colon carcinoma laminin-binding protein,
  • 37LRP,
  • NEM/1CHD4,
  • laminin receptor 1,
  • LRP/LR,
  • 40S ribosomal protein SA,
  • Laminin-binding protein precursor p40,
  • Multidrug resistance-associated protein MGr1-Ag,
  • LAMR1,
  • 67kD, ribosomal protein SA,
  • LBP/p40,
  • LBP,
  • ribosomal protein SA,
  • LRP,
  • 34/67 kDa laminin receptor,
  • LAMBR,
  • 67LR,
  • LamR,
  • p40,
  • RSSA,


Laminins, a family of extracellular matrix glycoproteins, are the major noncollagenous constituent of basement membranes. They have been implicated in a wide variety of biological processes including cell adhesion, differentiation, migration, signaling, neurite outgrowth and metastasis. Many of the effects of laminin are mediated through interactions with cell surface receptors. These receptors include members of the integrin family, as well as non-integrin laminin-binding proteins. The amino acid sequence of laminin receptor 1 is highly through evolution, suggesting a key biological function. It has been observed that the level of the laminin receptor transcript is higher in colon carcinoma tissue and lung cancer cell line than their normal counterparts. Also, there is a correlation between the upregulation of this polypeptide in cancer cells and their invasive and metastatic phenotype. Cell-adhesive protein LAMR1 plays an important role in the processes of cancer proliferation, invasion and metastasis. LAMR1 antigens have been found to be targets of autoantibodies in subjects newly diagnosed with lung cancer.


QA State: Accepted
Type: Protein
Short Name:


The following organs have data associated with this biomarker…



Phase: Three
QA State: Under Review


LAMR1, previously found to be the target of autoantibodies in newly diagnosed subjects with lung cancer, is also associated with autoantibodies in sera collected at the pre-symptomatic stage. These findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens, including LAMR1.

Performance Comment

The findings of this study suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens. Investigation of LAMR1 (RPSA) is ongoing.

Supporting Study Data

The following studies/protocols provide evidence supporting RPSA indications for the Lung…

No supporting studies or protocols found.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.


No associated studies or protocols found.


Mutation Statistics

Gene Name: RPSA
UniProt Accession #: P08865
Mutated Sites Count: 33
Associated Pubmed ID Count 7
CancerDO Count 16
Affected Protein Function Sites Count: 4

View in BioMuta